Publications

Filter Publications By:

Encorafenib / Cancer

07/01/2016

ESMO World Congress of Gastrointestinal Cancer

Combination of Encorafenib and Cetuximab With or Without Alpelisib in Patients With Advanced BRAF-Mutant (BRAFm) Colorectal Cancer: Phase 2 Results

J. Tabernero, et al.

Binimetinib / Cancer

06/06/2016

American Society of Clinical Oncology Meeting

Results of NEMO: A phase III trial of binimetinib (BINI) vs dacarbazine (DTIC) in NRAS-mutant cutaneous melanoma

R. Dummer, et al.

Encorafenib / Cancer

06/01/2016

American Society of Clinical Oncology Meeting

Phase 2 results: encorafenib (ENCO) and cetuximab (CETUX) with or without alpelisib (ALP) in patients with advanced BRAF-mutant colorectal cancer (BRAFm CRC)

J. Tabernero, et al.

Binimetinib / Cancer

01/21/2016

American Society of Clinical Oncology GI 2016

A Phase I Study of MEK162 and FOLFOX in chemotherapy-resistant metastatic colorectal cancer

M. Cho, et al.

Filanesib / Multiple Myeloma

12/07/2015

American Society of Hematology Annual Meeting 2015

Phase 2 Study of Carfilzomib With or Without Filanesib in Patients With Advanced Multiple Myeloma (MM)

J. Zonder, et al.

Filanesib / Multiple Myeloma

12/06/2015

American Society of Hematology Annual Meeting 2015

Phase 1 Study of the Novel Kinesin Spindle Protein Inhibitor Filanesib + Carfilzomib in Patients with Relapsed and /or Refractory Multiple Myeloma (RRMM)

J. Shah, et al.

Filanesib / Multiple Myeloma

12/05/2015

American Society of Hematology Annual Meeting 2015

Mechanisms Underlying the Synergistic Interaction of Filanesib with Pomalidomide and Dexamethasone (FPD) in Multiple Myeloma

S. Hernandez-Garcia, et al.

Binimetinib / Cancer

09/28/2015

European Cancer Congress

A Phase 1b/2 Study of Ribociclib (LEE011; CDK4/6 inhibitor) in Combination With Binimetinib (MEK162; MEK inhibitor) in Patients With NRAS‐Mutant Melanoma

C. van Herpen, M.D., Ph.D, et al.

Binimetinib / Cancer

09/27/2015

European Cancer Congress

LOGIC2: Phase 2, Multi-center, Open-label Study of Sequential Encorafenib/Binimetinib Combination Followed by a Rational Combination with Targeted Agents After Progression, to Overcome Resistance in Adult Patients with Locally Advanced or Metastatic BRAF V600 Melanoma

R. Dummer, M.D., et al.

Encorafenib / Cancer

07/04/2015

ESMO World Congress of Gastrointestinal Cancer

Phase 1b/2 Study of the Selective BRAF V600 Inhibitor Encorafenib (LGX818) Combined With Cetuximab With or Without the α‐Specific PI3K Inhibitor Alpelisib (BYL719) in Patients With Advanced BRAF‐Mutant Colorectal Cancer

E. Elez, et al.